Other substances

S2GΔHR2 I3-01v9 SApNP

An experimental COVID-19 protein nanoparticle vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

S2GΔHR2 I3-01v9 SApNP is an experimental self-assembling protein nanoparticle vaccine. Glycine-capped SARS-CoV-2 Spike protein with a heptad repeat 2 deletion represents the immunogen multivalently displayed on the nanoparticle’s surface. The nanoparticle elicited robust neutralizing antibody and T cell responses in mice (He et al., 2021).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates
Spike protein Biophysical assay Animal model In vitro 		in vitro binding assay; in vitro biophysical assay; EM; BALB/c mice 13.12

The nanoparticle elicited robust neutralizing antibody and T cell responses in mice.

 Mar/19/2021
Export (.csv)